From £6.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Results: VRCI

Search articles by EPIC code
EPIC VRCI
views

Verici Dx – emphasises “Certificate of Compliance”, but what’s the financial outlook?

Previously writing on transplant platform company Verici Dx (VRCI), in September with the shares falling to 17.5p I reviewed was the fundraise for accelerated progress or to avert cash crunch ahoy?, concluding continue to avoid. The shares most recently closed at 7.5p, but what of them currently up 20% today on the back of a “CLIA Certificate of Compliance” announcement.

EPIC VRCI
views

Verici Dx – was the “fundraise to… continue the accelerated progress” or to avert cash crunch ahoy?...

Previously writing on transplant platform company Verici Dx (VRCI), in March I concluded ‘if the cash is not soon needed, why place now? With the cash burn and a pre-fundraise market cap at even the current 36p share price of above £51 million, avoid’. With a “Commercial Team Appointments” announcement now following results, what do I think now?...

EPIC VRCI
views

Verici Dx – “fundraise to… continue the accelerated progress”, or to avert cash crunch ahoy?...

Verici Dx (VRCI), a developer of clinical diagnostics for organ transplant, has announced a placing of “at least £10.0 million” at 35p per share, stating it “intends to use the net proceeds of the fundraise to… continue the accelerated progress the company has experienced to date”. So what of currently a 4% share price fall in response?...

Page 1 of 1 (5 articles)
Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Complete Coverage

Recent Comments